Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc.

The KIMS Cancer Centre has successfully treated a patient suffering from Cutaneous T-cell Lymphoma using Electron Beam Therapy (EBT), a specialized radiation technique designed to precisely target ...

Marking a milestone in precision oncology, Concord treats a rare choroidal melanoma case with cutting-edge proton therapy.

While radiation treatments designed to kill cancer cells have come a long way, scientists and doctors are always exploring ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

Beam Therapeutics Inc. research and ratings by Barron's. View BEAM revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Learn about the executive team and board of directors at Beam Therapeutics Inc (BEAM:XNAS) and review their bios and compensation over the latest fiscal years.

Cathie Wood’s ARK ETFs disclosed their daily trades for Thursday, 3rd July 2025, with a mix of buys and sells across various sectors. The most significant trade of the day involved the sale of KOMATSU ...

Review Beam Therapeutics Inc (BEAM:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Earlier this month, Beam Therapeutics reported updated data from a phase I/II study, which showed that treatment with BEAM-101 led to a robust and durable increase in fetal hemoglobin and a ...